What Determines the Shape of the Probability Weighting Function?

When valuing risky prospects, people typically overweight small probabilities and underweight medium and large probabilities, but there is vast heterogeneity in individual behavior. We explore the relationship between person-specific probability weights, estimated from investment decisions in a laboratory experiment, and personal characteristics. We find considerable interaction effects with gender. While women’s probability weighting is strongly and significantly susceptible to mood states, men’s is not. Moreover, we show that cheerful and optimistic people weight probabilities of investment gains more favorably than do pessimistic people. People who calculate expected payoffs are less prone to probability distortions than those who do not use a lottery’s expected value as a decision criterion. None of the factors studied impact subjects’ valuations of monetary outcomes.Probability Weighting Function, Prospect Theory, Risk Aversion, Gender Differences

Multimodal approach to estimate the ocular movements during EEG recordings: a coupled tensor factorization method

International audienceThis paper deals with coupled tensor factorization. A relaxed criterion derived from the advanced coupled matrix-tensor factorization (ACMTF) proposed by Acar et al. is described. The proposed relaxed ACMTF (RACMTF) criterion is based on weaker assumptions that are thus more often satisfied when dealing with actual data. Numerical simulations show the benefit of using jointly two data sets when the underlying factors are highly correlated, especially if one of the modality is less noisy than the other one. The proposed method is finally applied on actual Gaze&EEG data to estimate the ocular artifacts into the EEG recordings

Finding the event structure of neuronal spike trains

Contains fulltext : 91821.pdf (publisher's version ) (Closed access

Evaluating a Novel Class of Biomaterials: Magnesium-Containing Layered Double Hydroxides

Metallic magnesium and compounds such as magnesium hydroxide Mg(OH)2 have been shown to have osteoconductive properties under experimental conditions and are gaining an increasing interest in the field of degradable biomaterials. The application of the compounds as implant coatings could support implant incorporation, resulting in an increased period of use of the implants. A variety of Mg-containing Layered Double Hydroxides (Mg-LDHs) has been synthesized and examined. These materials have been tested in various in vitro and in vivo studies; the latter took place in different sites like in the middle ear or in the condyle of New Zealand White Rabbits. In the latest study newly formed bone could be found around the Mg-Al-CO3-LDH pellets, making it a promising compound for bone-healing applications.DFG/SFB/59

Information Theory Filters for Wavelet Packet Coefficient Selection with Application to Corrosion Type Identification from Acoustic Emission Signals

The damage caused by corrosion in chemical process installations can lead to unexpected plant shutdowns and the leakage of potentially toxic chemicals into the environment. When subjected to corrosion, structural changes in the material occur, leading to energy releases as acoustic waves. This acoustic activity can in turn be used for corrosion monitoring, and even for predicting the type of corrosion. Here we apply wavelet packet decomposition to extract features from acoustic emission signals. We then use the extracted wavelet packet coefficients for distinguishing between the most important types of corrosion processes in the chemical process industry: uniform corrosion, pitting and stress corrosion cracking. The local discriminant basis selection algorithm can be considered as a standard for the selection of the most discriminative wavelet coefficients. However, it does not take the statistical dependencies between wavelet coefficients into account. We show that, when these dependencies are ignored, a lower accuracy is obtained in predicting the corrosion type. We compare several mutual information filters to take these dependencies into account in order to arrive at a more accurate prediction

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen

Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007

BackgroundParkinson's disease (PD) is the second most common neurodegenerative disorder. People with PD, their families, scientists, health care providers, and the general public are increasingly interested in identifying environmental contributors to PD risk.MethodsIn June 2007, a multidisciplinary group of experts gathered in Sunnyvale, California, USA, to assess what is known about the contribution of environmental factors to PD.ResultsWe describe the conclusions around which they came to consensus with respect to environmental contributors to PD risk. We conclude with a brief summary of research needs.ConclusionsPD is a complex disorder, and multiple different pathogenic pathways and mechanisms can ultimately lead to PD. Within the individual there are many determinants of PD risk, and within populations, the causes of PD are heterogeneous. Although rare recognized genetic mutations are sufficient to cause PD, these account for < 10% of PD in the U.S. population, and incomplete penetrance suggests that environmental factors may be involved. Indeed, interplay among environmental factors and genetic makeup likely influences the risk of developing PD. There is a need for further understanding of how risk factors interact, and studying PD is likely to increase understanding of other neurodegenerative disorders

Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future

There are a number of limitations to using conventional diagnostic markers for patients with clinical suspicion of infection. As a consequence, unnecessary and prolonged exposure to antimicrobial agents adversely affect patient outcomes, while inappropriate antibiotic therapy increases antibiotic resistance. A growing body of evidence supports the use of procalcitonin (PCT) to improve diagnosis of bacterial infections and to guide antibiotic therapy. For patients with upper and lower respiratory tract infection, post-operative infections and for severe sepsis patients in the intensive care unit, randomized-controlled trials have shown a benefit of using PCT algorithms to guide decisions about initiation and/or discontinuation of antibiotic therapy. For some other types of infections, observational studies have shown promising first results, but further intervention studies are needed before use of PCT in clinical routine can be recommended. The aim of this review is to summarize the current evidence for PCT in different infections and clinical settings, and discuss the reliability of this marker when used with validated diagnostic algorithms